1. Home
  2. GERN vs BOW Comparison

GERN vs BOW Comparison

Compare GERN & BOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.29

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$27.30

Market Cap

734.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
BOW
Founded
1990
2020
Country
United States
United States
Employees
258
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
808.3M
734.3M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
GERN
BOW
Price
$1.29
$27.30
Analyst Decision
Hold
Buy
Analyst Count
3
7
Target Price
$2.17
$32.29
AVG Volume (30 Days)
12.2M
138.6K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.26
EPS
N/A
0.48
Revenue
N/A
$551,589,000.00
Revenue This Year
$26.91
$21.31
Revenue Next Year
$43.75
$19.15
P/E Ratio
N/A
$56.83
Revenue Growth
N/A
29.58
52 Week Low
$1.04
$21.21
52 Week High
$2.01
$37.98

Technical Indicators

Market Signals
Indicator
GERN
BOW
Relative Strength Index (RSI) 51.67 56.67
Support Level $1.22 $23.65
Resistance Level $1.30 $27.80
Average True Range (ATR) 0.07 0.99
MACD 0.02 0.07
Stochastic Oscillator 80.00 82.58

Price Performance

Historical Comparison
GERN
BOW

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

Share on Social Networks: